Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

for
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT03412877

Phase 2, Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

for
Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer,
Location: Toronto, Pittsburgh PA, Milwaukee WI, Houston TX
Sponsor: UMC Utrecht

Sex: All

Age: 18+

Code: NCT04075305

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

for
Advanced Solid Tumor, Advanced Breast Cancer,
Location: Durham NC, Columbus OH, Nashville TN, Denver CO,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06120283

Phase 1, Recruiting

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

for
Bladder Cancer, Head and Neck Squamous Cell Carcinoma,
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 18+

Code: NCT03740256

Phase 1, Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

for
Neoplasms, Brain, Glioblastoma Multiforme,
Location: Birmingham AL, St Louis MO, Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 3 - 22

Code: NCT03911388

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

for
Advanced Solid Tumor, Melanoma, Head and Neck Cancer,
Location: New Haven CT, New York NY, Baltimore MD, Rockville MD,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06172478

Phase 2, Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

for
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Location: New York NY, Jacksonville FL, Ann Arbor MI, Chicago IL,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06401356

Phase 3, Recruiting

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

for
Advanced Solid Tumor,
Location: Boston MA, Lebanon NH, Morristown NJ,
Sponsor: Vaxiion Therapeutics

Sex: All

Age: 18+

Code: NCT05901285

Phase 1, Recruiting

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

for
Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Hickory NC,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT06952010

Phase 1, Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

for
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm,
Location: Riverhead NY, Patchogue NY, Port Jefferson Station NY,
Sponsor: BriaCell Therapeutics Corporation

Sex: All

Age: 18+

Code: NCT06072612

Phase 3, Recruiting

Genomic Investigation of Unusual Responders

for
Cancer, Breast Cancer, Non-small Cell Lung Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03740503

Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

for
Advanced HR+/HER2- Breast Cancer,
Location: Boston MA, New York NY, Montreal, Toronto,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06726148

Phase 1, Phase 2, Recruiting

Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada

for
Cancer, Prostate Cancers, Breast Cancers, Colon Cancer,
Location: Halifax, Montreal, Toronto, Calgary, Vancouver
Sponsor: University of Calgary

Sex: All

Age: 18+

Code: NCT06960291

Recruiting

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

for
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Location: Valhalla NY, The Bronx NY, Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 1 - 40

Code: NCT03465592

Phase 1, Phase 2, Recruiting

Immune Resistance Interrogation Study

for
Cancer, Solid Tumor, Metastatic Cancer, Immune Resistance
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT04243720

Recruiting
New

Three Times Weekly Symptom Screening for Children With Cancer

for
Cancer, Relapsed Cancer
Location: Toronto
Sponsor: The Hospital for Sick Children

Sex: All

Age: 2 - 18

Code: NCT04275102

Recruiting
New

Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery

for
Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT07631026

Recruiting
New

MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)

for
HER2-positive Breast Cancer
Location: Miami FL
Sponsor: Imagion Biosystems, Inc.

Sex: Female

Age: 18+

Code: NCT07885683

Phase 1, Phase 2, Recruiting
New

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

for
Advanced Solid Tumors
Location: Huntersville NC
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07863024

Phase 1, Phase 2, Recruiting
New

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

for
Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07553390

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial